EP Patent

EP3999180B1 — Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide

Assigned to Cytokinetics Inc · Expires 2024-05-08 · 2y expired

What this patent protects

Patent listed against null.

Drugs covered by this patent

Patent Metadata

Patent number: EP3999180B1
Jurisdiction: EP
Classification: —
Expires: 2024-05-08
Drug substance claim: No
Drug product claim: No
Assignee: Cytokinetics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.